Introduction {#sec1}
============

Breast cancer is the most frequently diagnosed tumor and a leading cause of cancer-related deaths among women worldwide \[[@B1]\]. Early diagnosis and treatment strategies including surgery, chemotherapy, radiotherapy, endocrine agents, and biological targeting agents have reduced patient morbidity and mortality; however, the prognosis of breast cancer remains poor. While clinical, pathological, and molecular features are widely used for establishing prognostics and predicting outcomes, finding more sensitive and specific biomarkers as surrogates of these features is the current trend in breast cancer research \[[@B2]\].

Ribonucleotide reductase M2 subunit (*RRM2*), a rate-limiting enzyme for DNA synthesis and repair, displays vital roles in many critical cellular processes such as cell proliferation, invasiveness, migration, angiogenesis, and senescence \[[@B3]\]. *RRM2* is frequently overexpressed in various malignancies and functions like a tumor driver \[[@B4]\]. Accumulating evidence has suggested that targeting *RRM2* may be a novel strategy for cancer treatment. For example, *RRM2* protected glioblastoma cells from endogenous replication stress, DNA damage, and apoptosis; *RRM2* inhibition sensitized glioblastoma cells to agent treatment \[[@B9]\]. Knockdown of *RRM2* attenuated melanoma growth both *in vitro* and *in vivo*, which correlated with maintenance of senescence-associated cell-cycle arrest \[[@B10]\]. In terms of breast cancer, both genetic suppression by RNA interference approach and pharmacological inhibition by small molecular antagonist of *RRM2* gene significantly reversed tamoxifen-resistant cell proliferation, reduced cell motility, activated pro-apoptotic pathways, and decreased tumor growth \[[@B11]\]. Moreover, it was reported that *RRM2* was associated with chemoresistance of breast cancer cells to adriamycin; suppression of *RRM2* synthesis could enhance the chemosensitivity to toxic insult \[[@B14]\]. Taken together, these findings suggest that *RRM2* may act not only as an oncogene, but also as a promising prognostic biomarker and potential therapeutic target in cancer.

Therefore, in the present study, we evaluated the significance of *RRM2* gene expression in breast cancer by using bioinformatics analysis of the clinical parameters and survival data in several large online databases.

Materials and methods {#sec2}
=====================

Oncomine {#sec2-1}
--------

The Oncomine (<http://www.oncomine.org>), an online database containing microarray expression data from a variety of human cancers, was used to determine the level of *RRM2* in breast cancer patients and normal individuals with the threshold of fold change ≥ 2, *P*-value ≤ 1E-4, and gene rank ≥ top 10% \[[@B15]\]. Gene co-expressed with *RRM2* was analyzed and displayed as a heat map.

Breast Cancer Gene-Expression Miner {#sec2-2}
-----------------------------------

The Breast Cancer Gene-Expression Miner v4.1 (bcGenExMiner v4.1, <http://bcgenex.centregauducheau.fr/BC-GEM>), a mining tool of published annotated genomics data, was utilized to evaluate the association between *RRM2* gene and clinical parameters, as well as the relevance with metastatic relapse event \[[@B16],[@B17]\]. The correlation between *RRM2* and *KIF11* were generated using the correlation module.

PrognoScan {#sec2-3}
----------

The PrognoScan (<http://www.prognoscan.org/>) is a large database with clinical annotation and a web-based tool for assessing the biological relationship between gene expression and prognostic information including overall survival, relapse-free survival, distant metastasis-free survival, disease-specific survival, and disease-free survival in breast cancer patients \[[@B18]\]. Cox *P*-values and hazard ratio (HR) with 95% confidence intervals were calculated automatically.

Kaplan--Meier Plotter {#sec2-4}
---------------------

The Kaplan--Meier Plotter (<http://kmplot.com/analysis/>), a platform containing gene expression information and survival data of 5143 clinical breast cancer patients, was applied to verify the prognostic value of *RRM2* gene in overall survival, relapse-free survival, and distant metastasis-free survival \[[@B19]\].

UCSC Xena {#sec2-5}
---------

The heat map of *RRM2* and *KIF11* in the same patient cohort were constructed by data mining in TCGA Breast Cancer using the UCSC Xena browser (<http://xena.ucsc.edu/>).

Results {#sec3}
=======

Increased expression of *RRM2* gene in breast cancer patients {#sec3-1}
-------------------------------------------------------------

We first checked the expression of *RRM2* gene in 20 types of malignant tumor using the Oncomine database. Increased level of *RRM2* (red) was observed in gastrointestinal cancers, gynecological cancers, urogenital cancers, and breast cancer ([Figure 1](#F1){ref-type="fig"}). Our analysis also revealed that *RRM2* was significantly higher expressed in male breast carcinoma, intraductal cribriform breast adenocarcinoma, invasive breast carcinoma, invasive lobular breast carcinoma, invasive ductal breast carcinoma, ductal breast carcinoma *in situ*, invasive ductal breast carcinoma epithelia, and ductal breast carcinoma, compared with the corresponding normal tissues ([Figure 2](#F2){ref-type="fig"}A--H and [Table 1](#T1){ref-type="table"}).

![Expression of *RRM2* gene in 20 types of malignant tumor and corresponding normal tissues using the Oncomine database\
Red and blue represent the numbers of datasets with statistically significant (*P*\<0.05) increased and decreased levels of *RRM2* gene, respectively. Cell color is determined by the best gene rank percentile for the analyses within the cell, and the gene rank was analyzed by percentile of target genes in the top of all genes measured by each study.](bsr-39-bsr20182062-g1){#F1}

![Box plot comparing *RRM2* expression in normal individuals and breast cancer patients derived from the Oncomine database\
Analysis is shown for male breast carcinoma (**A**), intraductal cribriform breast adenocarcinoma (**B**), invasive breast carcinoma (**C**), invasive lobular breast carcinoma (**D**), invasive ductal breast carcinoma (**E**), ductal breast carcinoma *in situ* (**F**), invasive ductal breast carcinoma epithelia (**G**), and ductal breast carcinoma (**H**). \* stands for the maximum and minimum values.](bsr-39-bsr20182062-g2){#F2}

###### *RRM2* expression in different subtypes of breast cancer and normal tissues using the Oncomine database

  Breast cancer subtype                          *P*-value\*   *t*test   Fold change   Patient number   Reference
  ---------------------------------------------- ------------- --------- ------------- ---------------- ----------------
  Male breast carcinoma                          1.95E-19      19.864    9.832         3                TCGA
  Intraductal cribriform breast adenocarcinoma   1.32E-17      18.111    8.163         3                TCGA
  Invasive breast carcinoma                      1.24E-28      14.159    5.003         76               TCGA
  Invasive lobular breast carcinoma              3.51E-16      9.962     4.522         36               TCGA
  Invasive ductal breast carcinoma               2.51E-38      20.624    5.282         389              TCGA
  Ductal breast carcinoma *in situ* epithelia    2.05E-5       5.180     12.792        9                PMID: 19187537
  Invasive ductal breast carcinoma epithelia     9.52E-5       4.513     10.319        9                PMID: 19187537
  Ductal breast carcinoma                        6.37E-6       9.800     39.696        40               PMID: 16473279

\*Statistical significance was determined by the Student's *t*test.

*RRM2* expression and clinical parameters in breast cancer patients {#sec3-2}
-------------------------------------------------------------------

By using the bc-GenExMiner online tool, we next compared *RRM2* expression among groups of patients, according to different clinical parameters. Regarding age, there was no significant difference between ≤51- and \>51-year group ([Figure 3](#F3){ref-type="fig"}A and [Table 2](#T2){ref-type="table"}). The Scarff--Bloom--Richardson (SBR) is a histological grade that evaluates tubule formation, nuclear characteristics of pleiomorphism, and mitotic index. The Nottingham Prognostic Index (NPI) has been validated to stratify patients into additional prognostic groups according to tumor size, lymph node stage, and tumor grade. Breast cancer patients with more advanced SBR grade and NPI tended to express higher *RRM2* gene ([Figure 3](#F3){ref-type="fig"}B,C). Estrogen receptor (ER) and progesterone receptor (PR) status were negatively associated with *RRM2* expression ([Figure 3](#F3){ref-type="fig"}D,E and [Table 2](#T2){ref-type="table"}). Conversely, human epidermal growth factor receptor-2 (HER-2) status was confirmed to correlate positively with *RRM2* expression ([Figure 3](#F3){ref-type="fig"}F and [Table 2](#T2){ref-type="table"}). Breast cancer patients with positive nodal status (N) showed increased level of *RRM2* than those with negative nodal status ([Figure 3](#F3){ref-type="fig"}G and [Table 2](#T2){ref-type="table"}). Besides, we found that *RRM2* was strongly elevated in basal-like subtype with respect to non-basal-like subtype; the same pattern of change was also observed in triple-negative breast cancer (TNBC) patients ([Figure 3](#F3){ref-type="fig"}H,I and [Table 2](#T2){ref-type="table"}).

![Box plot evaluating *RRM2* expression among groups of patients according to different clinical parameters using the bc-GenExMiner software\
Analysis is shown for age (**A**), SBR (**B**), NPI (**C**), ER (**D**), PR (**E**), HER-2(**F**), nodal status (**G**), basal-like status (**H**), and triple-negative status (**I**).](bsr-39-bsr20182062-g3){#F3}

###### Relationship between *RRM2* expression and clinical parameters of breast cancer patients using the bc-GenExMiner database

  Variables                Patient number   *RRM2* mRNA   *P*-value\*
  ------------------------ ---------------- ------------- -------------
  Age (years)                                             0.1700
  ≤51                      1317             −             
  \>51                     2015             −             
  ER                                                      \<0.0001
  Negative                 1468             Increased     
  Positive                 3810             −             
  PR                                                      \<0.0001
  Negative                 946              Increased     
  Positive                 1439             −             
  HER-2                                                   \<0.0001
  Negative                 1409             −             
  Positive                 201              Increased     
  Nodal status                                            0.0175
  Negative                 2447             −             
  Positive                 1509             Increased     
  Basal-like status                                       \<0.0001
  Non-basal-like           4089             −             
  Basal-like               1112             Increased     
  Triple-negative status                                  \<0.0001
  Non-triple-negative      3986             −             
  Triple-negative          374              Increased     

\*Statistical significance was determined by the Welch's test.

*RRM2* expression and prognosis in breast cancer patients {#sec3-3}
---------------------------------------------------------

We then investigated the prognostic value of *RRM2* gene. The Kaplan--Meier curves indicated that lower level of *RRM2* correlated with preferable overall survival ([Figure 4](#F4){ref-type="fig"}A). While breast cancer patients with up-regulated *RRM2* demonstrated worse relapse-free survival ([Figure 4](#F4){ref-type="fig"}B), patients with decreased *RRM2* expression presented better distant metastasis-free survival ([Figure 4](#F4){ref-type="fig"}C). Furthermore, *RRM2* exerted positive effect on metastatic relapse event, as suggested by the forest plot using the bc-GenExMiner tool ([Figure 4](#F4){ref-type="fig"}D). The PrognoScan database showed that overexpression of *RRM2* was significantly associated with inferior overall survival, relapse-free survival, distant metastasis-free survival, disease-specific survival, and disease-free survival ([Table 3](#T3){ref-type="table"}).

![Survival curve and forest plot evaluating the prognostic value of *RRM2*\
Analysis is shown for overall survival (**A**), relapse-free survival (**B**), distant metastasis-free survival (**C**) using the Kaplan--Meier Plotter, and forest plot of metastatic relapse event using the bc-GenExMiner database (**D**).](bsr-39-bsr20182062-g4){#F4}

###### *RRM2* expression and survival data of breast cancer patients using the PrognoScan database

  Dataset          Probe name     End point                          Patient number   Cox *P*-value   HR
  ---------------- -------------- ---------------------------------- ---------------- --------------- ---------------------
  GSE12276         209773_s\_at   Relapse-free survival              204              0.001805        1.36 \[1.12--1.65\]
  GSE6532-GPL570   209773_s\_at   Relapse-free survival              87               0.025415        1.39 \[1.04--1.87\]
  GSE6532-GPL570   209773_s\_at   Distant metastasis-free survival   87               0.025415        1.39 \[1.04--1.87\]
  GSE9195          209773_s\_at   Relapse free survival              77               0.029912        2.01 \[1.07--3.78\]
  GSE9195          209773_s\_at   Distant metastasis-free survival   77               0.027181        2.30 \[1.10--4.82\]
  GSE11121         209773_s\_at   Distant metastasis-free survival   200              0.001108        1.99 \[1.32--3.02\]
  GSE2034          209773_s\_at   Distant metastasis-free survival   286              0.001001        1.64 \[1.22--2.20\]
  GSE1456-GPL96    209773_s\_at   Overall survival                   159              0.000074        2.41 \[1.56--3.73\]
  GSE1456-GPL96    209773_s\_at   Relapse-free survival              159              0.000028        2.53 \[1.64--3.90\]
  GSE1456-GPL96    209773_s\_at   Disease-specific survival          159              0.000014        3.23 \[1.90--5.47\]
  GSE7378          201890_at      Disease-free survival              54               0.021327        1.99 \[1.11--3.59\]
  GSE7378          209773_s\_at   Disease-free survival              54               0.013458        2.36 \[1.19--4.67\]
  E-TABM-158       209773_s\_at   Disease-specific survival          117              0.026992        0.71 \[0.53--0.96\]
  GSE3494-GPL96    209773_s\_at   Disease-specific survival          236              0.000122        2.07 \[1.43--3.00\]
  GSE4922-GPL96    209773_s\_at   Disease-free survival              249              0.000007        1.96 \[1.46--2.63\]
  GSE2990          209773_s\_at   Relapse-free survival              62               0.016824        1.73 \[1.10--2.70\]
  GSE2990          209773_s\_at   Distant metastasis-free survival   54               0.012179        2.04 \[1.17--3.56\]
  GSE7390          209773_s\_at   Overall survival                   198              0.012109        1.35 \[1.07--1.70\]
  GSE7390          209773_s\_at   Distant metastasis-free survival   198              0.049656        1.24 \[1.00--1.54\]

Co-expression of *RRM2* gene {#sec3-4}
----------------------------

To further investigate the underlying regulation of *RRM2* in breast cancer, data mining of the co-expression of *RRM2* gene was performed using the Oncomine database. The co-expression profile of *RRM2* was identified with a large cluster of 1802 genes across 61 breast carcinomas, and *KIF11* is a principal correlated gene ([Figure 5](#F5){ref-type="fig"}A). Data mining in bc-GenExMiner revealed a positive correlation between *RRM2* and *KIF11* ([Figure 5](#F5){ref-type="fig"}B). By comparing the *RRM2* and *KIF11* expression heat map derived from the UCSC Xena web-based tool, it was confirmed that *RRM2* expression gradually elevated with increasing *KIF11* transcript level, which was determined among a 50-gene qPCR assay (PAM50) breast cancer subtypes in TCGA database ([Figure 5](#F5){ref-type="fig"}C). These data indicated that *RRM2* could be associated with the *KIF11* signaling pathways in breast cancer.

![Co-expression of *RRM2* gene\
(**A**) Co-expression profile of *RRM2* identified using the Oncomine database. (**B**) Correlation between *RRM2* and *KIF11* expression in breast cancer analyzed using the bc-GenExMiner software. (**C**) Heat map of *RRM2* and *KIF11* expression across PAM50 breast cancer subtypes in the TCGA database obtained from the UCSC Xena web-based tool.](bsr-39-bsr20182062-g5){#F5}

Discussion {#sec4}
==========

*RRM2* plays vital roles in diverse cellular functions such as cell proliferation, invasiveness, migration, angiogenesis, senescence, and tumorigenesis \[[@B3]\]. It was reported that *RRM2* was associated with resistance of breast cancer cells to chemotherapy and endocrine agents and that targeting *RRM2* may be a novel strategy for cancer treatment \[[@B11]\]. However, the significance of *RRM2* expression in prognosis of breast cancer remains largely unclear.

In the present work, we analyzed the expression profile of *RRM2* by Oncomine database. *RRM2* gene was higher expressed in male breast carcinoma, intraductal cribriform breast adenocarcinoma, invasive breast carcinoma, invasive lobular breast carcinoma, invasive ductal breast carcinoma, ductal breast carcinoma *in situ*, invasive ductal breast carcinoma epithelia, and ductal breast carcinoma patients, with respect to normal individuals. By using the bc-GenExMiner online tool, we found that ER and PR were negatively correlated with *RRM2* expression. Conversely, SBR, NPI, HER-2 status, nodal status, basal-like status, and triple-negative status were positively related to *RRM2* level in breast cancer samples with respect to normal tissues. As known to all, patients with ER or PR negative, nodal positive, HER-2 positive, basal-like or triple-negative status generally display an unsatisfied therapeutic response and worse clinical outcome. Therefore, our results suggested that lower expression of *RRM2* may predict a better prognosis of breast cancer.

We further investigated the prognostic value of *RRM2* in breast cancer using the Kaplan--Meier Plotter, PrognoScan, and bc-GenExMiner databases. Patients with increased *RRM2* showed worse overall survival, relapse-free survival, distant metastasis-free survival, disease-specific survival, and disease-free survival. Additionally, high *RRM2* expression was correlated with an increased risk of metastatic relapse event, as suggested by the forest plot. These findings collectively demonstrated that the level of *RRM2* might be a useful predictive biomarker for prognosis of breast cancer. We finally analyzed the co-expression of *RRM2* using the Oncomine, bc-GenExMiner, and UCSC Xena web-based tools and confirmed that *KIF11* gene was positively correlated with *RRM2* expression. *KIF11*, a molecular motor protein involved in mitosis, was critical for proliferation and self-renewal in chemoresistant breast cancer cells \[[@B20]\]. *KIF11* knockdown inhibited tumor growth both *in vitro* and *in vivo*, and its expression was responsible for shorter survival time \[[@B21]\]. Thus, our data indicated that *RRM2* might contribute to breast cancer progression and drug insensitivity associated with *KIF11* expression.

In summary, the present bioinformatics analysis showed that *RRM2* was overexpressed in breast cancer patients with respect to normal tissues and was associated with a worse survival. *RRM2* could be used as a predictive biomarker for prognosis of breast cancer with co-expressed *KIF11* gene. Further studies are needed to more precisely elucidate the value of *RRM2* in evaluating breast cancer prognosis.
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